Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: Do disparities exist?

This publication has 30 references indexed in Scilit:

• Evaluation of EGFR mutation status in cytology specimens: An institutional experience
  Diagnostic Cytopathology, 2011
• Ethnic Differences in Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
  Journal of Clinical Oncology, 2006
• Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib
  Clinical Cancer Research, 2006
• Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer
  Clinical Cancer Research, 2005
• The Relationship between Epidermal Growth Factor Receptor Mutations and Clinicopathologic Features in Non–Small Cell Lung Cancers
  Clinical Cancer Research, 2005
• EGFR Mutations in Non–Small-Cell Lung Cancer: Analysis of a Large Series of Cases and Development of a Rapid and Sensitive Method for Diagnostic Screening With Potential Implications on Pharmacologic Treatment
  Journal of Clinical Oncology, 2005
• EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
  Proceedings of the National Academy of Sciences, 2004
• Implications and Prognostic Value of K-ras Mutation for Early-Stage Lung Cancer in Women
  JNCI: Journal of the National Cancer Institute, 1999
• Detection of K-ras mutations in lung carcinomas: relationship to prognosis.
  1996
• A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
  Journal of Chronic Diseases, 1987